Advertisement

Agents and Actions

, Volume 42, Issue 1–2, pp 29–33 | Cite as

Protective effects of papaverine salicylate in mouse ear dermatitis and PAF-induced rat paw oedema

  • E. de Bernardis
  • G. Leonardi
  • A. Caruso
  • V. M. C. Cutuli
  • M. Amico-Roxas
Inflammation

Abstract

Papaverine salicylate (MR-800) has been tested as a topical antiinflammatory agent in several models of skin inflammation in rodents, such as mouse ear dermatitis induced by croton oil, cantharidin or zymosan, and rat paw oedema induced by PAF. MR-800 exerted a dose-dependent inhibitory activity in all assays, when equimolar doses of sodium salicylate or papaverine were less effective, suggesting the existence of a favourable synergism between salicylate and papaverine.

Key words

Papaverine salicylate Croton oil Cantharidin Zymosan PAF 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    M. A. Stawiski, J. A. Powell, P. G. Lang, A. Schork, E. A. Duell and J. J. Voorhees,Papaverine: Its effects on cyclic AMP in vitro and psoriasis in vivo. J. Invest. Dermatol.64, 124–127 (1975).PubMedGoogle Scholar
  2. [2]
    G. A. Panteleeva and I. M. Gribov,Papaverin electrophoresis in therapy of patients with psoriasis and diffuse neurodermatitis. Vestn. Dermatol. Venerol.67, 26–28 (1991).Google Scholar
  3. [3]
    R. S. Cordeiro, P. M. Silva, M. A. Martins and B. B. Vargaftig,Salicylates inhibit PAF-acether-induced rat paw oedema when cyclooxygenase inhibitors are ineffective. Prostaglandins32, 719–727 (1986).PubMedGoogle Scholar
  4. [4]
    A. Bertelli, M. C. Breschi and F. Caciagli,Effects of cyclic nucleotides on the inflammatory reaction.Future Trends in Inflammation. (Eds. G. P. Velo, D. A. Willoughby and J. P. Giroud) pp. 267–276, Piccin Medical Books, Padua 1973.Google Scholar
  5. [5]
    J. Alanko, A. Riutta and H. Vapaatalo,Effects of catecholamines on eicosanoid synthesis with special reference to prostanoid/leukotriene ratio. Free Radic. Biol. Med.15, 677–688 (1992).Google Scholar
  6. [6]
    K. F. Swingle, M. J. Reiter and D. H. Schwartzmiller,Compason of croton oil and cantharidin induced inflammations of the mouse ear and their modification by topically applied drugs. Arch. Int. Pharmacodyn. Ther.254, 168–176 (1981).PubMedGoogle Scholar
  7. [7]
    F. Erdó, K. Török, P. Arányi and J. I. Székely,Zymosan induced mouse ear edema: A new animal model of inflammation. Pharmacol. Res.25(Suppl. 2), 236–237 (1992).Google Scholar
  8. [8]
    J. T. Lichtfield and F. Wilcoxon,A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther.96, 99 (1949).Google Scholar
  9. [9]
    H. Inoue, T. Mori, S. Shibata and Y. Koshihara,Modulation by glycyrrhetinic acid derivatives of TPA-induced mouse ear oedemar. Br. J. Pharmacol.96, 204–210 (1989).PubMedGoogle Scholar
  10. [10]
    B. Kirkhus, M. Glaso and O. P. Clausen,Multivariate flow cytometry of epidermal regeneration provoked by a skin irritant and a tumor promoter. Cytometry13, 267–274 (1992).PubMedGoogle Scholar
  11. [11]
    R. E. Honkanen.Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A. FEBS Lett.330, 283–286 (1993).PubMedGoogle Scholar
  12. [12]
    Y. M. Li and J. E. Casida,Cantharidin-binding protein: Identification as protein phosphatase 2A. Proc. Natl. Acad. Sci. USA89, 11867–11870 (1992).PubMedGoogle Scholar
  13. [13]
    Y. Imai, M. Hayashi and S. Ohishi,Involvement of platelet activating factor in zymosan-induced rat pleurisy. Lipids26 1408–1411 (1991).PubMedGoogle Scholar
  14. [14]
    J. Damas, G. Remacle Volon and V. Bourdon,Platelet-activating factor and the vascular effects of zymosan in rats. Eur. J. Pharmacol.231, 231–236 (1993).PubMedGoogle Scholar
  15. [15]
    M. A. Martins, P. M. Silva, H. C. Castro Faria Neto, P. T. Bozza, P. M. Dias, M. C. Lima, R. S. Cordeiro and B. B. Vargaftig,Pharmacological modulation of PAF-induced rat pleurisy and its role in inflammation by zymosan. Br. J. Pharmacol.96, 363–371 (1989).PubMedGoogle Scholar
  16. [16]
    A. I. Mallett and F. M. Cunningham,Structural identification of platelet activating factor inpsoriatic scale. Biochem. Biophys. Res. Commun.126, 192–198 (1985).PubMedGoogle Scholar
  17. [17]
    R. M. Barr, M. R. Judge, M. W. Greaves, A. I. Mallet, F. Lawlor, A. Black and R. Barlow,Platelet activating factor (PAF) and lyso-PAF in inflammed human skin. World Congress Inflammation '93, Abstract book (Eds.). p. 56, Vienna, October 10–15, 1993.Google Scholar
  18. [18]
    K. D. Cooper, J. J. Voorhees, G. J. Fisher, L. S. Chan, A. K. Gupta and O. Baadsgaard,Effects of cyclosporine on immunologic mechanisms in psoriasis. J. Am. Acad. Dermatol.23, 1318–1326 (1990).PubMedGoogle Scholar
  19. [19]
    L. Michel and L. Dubertret,Leukotriene B4 and platelet-activating factor in human skin. Arch. Dermatol. Res.284(Suppl. 1). S12-S17 (1992).PubMedGoogle Scholar
  20. [20]
    D. Tsikas, J. Fauler and J. C. Frolich,Analysis of cysteinyl leukotrienes and leukotriene B4 by gas chromatography-(tandem) mass spectrometry. Eicosanoids5 (suppl.), S7-S9 (1992).PubMedGoogle Scholar
  21. [21]
    R. D. Camp, A. I. Mallet, F. M. Cunningham, E. Wong, P. M. Woollard, P. Dowd, A. Kobza Black and M. W. Greaves,The role of chemo-attractant lipoxygenase products in the pathogenesis of psoriasis. Br. J. Dermatol.113 (Suppl. 28), 98–103 (1985).PubMedGoogle Scholar
  22. [22]
    K. D. Cooper, C. Hammerberg, O. Baadsgaard, J. T. Elder, L. S. Chan, D. N. Sauder, J. J. Voorhees and G. Fisher,IL-1 activity is reduced in psoriatic skin. Decreased IL-1 alpha and increased nonfunctional IL-1 beta. J. Immunol.144, 4593–4603 (1990).PubMedGoogle Scholar
  23. [23]
    C. Hammerberg, W. P. Arend, G. J. Fisher, L. S. Chan, A. E. Berger, J. S. Haskill, J. J. Voorhees and K. D. Cooper,Interleukin-1 receptor antagonist in normal and psoriatic epidermis. J. Clin. Invest.90, 571–583 (1992).PubMedGoogle Scholar
  24. [24]
    R. D. Camp and M. W. Greaves,Inflammatory mediators in the skin. Br. Med. Bull.43, 401–414 (1987).PubMedGoogle Scholar
  25. [25]
    K. Bergh, O. J. Iversen and H. Lysvand,Surprisingly high levels of anaphylatoxin C5a des Arg are extractable from psoriatic scales. Arch. Dermatol. Res.285, 131–134 (1993).PubMedGoogle Scholar
  26. [26]
    H. Takematsu and H. Tagami,Quantification of chemotactic peptides (C5a anaphylatoxin and IL-8) in psoriatic lesional skin. Arch. Dermatol.129, 74–80 (1993).PubMedGoogle Scholar
  27. [27]
    H. Takematsu and H. Tagami,Generation of terminal complement complexes in psoriatic lesional skin. Dermatology185, 246–250 (1992).PubMedGoogle Scholar
  28. [28]
    J. Pec, M. Strmenova, E. Palencarova, R. Pullmann, S. Funiakova, P. Visnovsky, J. Buchanec and Z. Lazarova,Salicylate intoxication after use of topical salicylic acid ointment by a patient with psoriasis. Cutis50, 307–309 (1992).PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag 1994

Authors and Affiliations

  • E. de Bernardis
    • 1
  • G. Leonardi
    • 1
  • A. Caruso
    • 1
  • V. M. C. Cutuli
    • 1
  • M. Amico-Roxas
    • 1
  1. 1.Institute of PharmacologyUniversity of Catania Medical SchoolCataniaItaly

Personalised recommendations